

HEALEY ALS Platform Trial

Weekly Q&A – August 5, 2021



Healey Center

Sean M. Healey & AMG Center
for ALS at Mass General




The AMG Foundation

Perpetual Adaptive Trial





Shared Placebo; Randomization Ratio 3:1

Open Label Extension (OLE) offered



Enrollment Updates (as of August 5, 2021)

- **686** individuals with ALS signed informed consent
- **541** individuals were assigned to a regimen
- **492** individuals were randomized within a regimen (active or placebo)
- **166** have entered the Open Label Extension (OLE)

- **133** individuals were randomized within Regimen A  >146
- **151** individuals were randomized within Regimen B  >154
- **151** individuals were randomized within Regimen C  >153
- **57** individuals were randomized within Regimen D  >65

Thank You


This breakthrough trial would not be possible without your partnership

How to Find a Center Near You

Sean M. Healey & AMG
Center for ALS

About the Healey Center Clinical Care Patient & Family Resources

Map of Participating Sites



HEALEY ALS Platform Trial Locations
This map was created by a user. Learn how to create your own.

List of Participating Sites by State

Site	State	Contact Information
Barrow Neurological Institute	Arizona	Jessie Duncan

52 sites are actively enrolling

Contact Info of Participating Sites by State



<https://www.massgeneral.org/neurology/als/research/platform-trial-sites>

Patient Navigator



Catherine Small

Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail: healeyalsplatform@mgh.harvard.edu



To see whether you might qualify,
view the list of eligibility criteria:

<https://bit.ly/3p4PrLL>



Send us webinar ideas!

- **Biomarkers**
- **Biostatistics / Trial Design**
- **Get to know our sites**



Upcoming Guest Speakers:

Aug 12th- Michael Weiss, MD, FAAN (University of Washington, WA)

Aug 19th- Laura Foster, MD (University of Colorado, CO)

Aug 26th- Niraja Suresh, MD (University of South Florida, FL)

Sept 9th- Jennifer DiMartino (Executive Director, ALS ONE)

For More Updates

- **Weekly webinars**

The idea of came from our Patient Advisory Committee: we are excited to be talking with you on a weekly basis and take any questions you might have

- **Find the schedule and registration links on our website**

<https://www.massgeneral.org/neurology/als/research/platform-trial-news/>

Previously: Drug mechanism of action and science webinars



- | | | |
|---------|-----------------------|---|
| Jan 21- | Prilenia/Pridopidine | (<u>recorded</u> - https://bit.ly/3ad3qel) |
| Feb 4 | - Clene/CNM-Au8 | (<u>recorded</u> - https://bit.ly/3jB3WWt) |
| Feb 18- | Biohaven/Verdiperstat | (<u>recorded</u> - https://bit.ly/301qdDR) |
| Feb 25- | UCB/Zilucoplan | (<u>recorded</u> - https://bit.ly/3b3cpyS) |